ImmunityBio Shares Surge on Stellar ANKTIVA Performance and Revenue Forecast

ImmunityBio projects 2025 revenue of ~$113M, a 700% jump, fueled by global expansion of its immunotherapy drug ANKTIVA and narrower quarterly losses.

ImmunityBio has announced a dramatic surge in projected revenue for 2025, driven by the explosive performance of its immunotherapy drug, ANKTIVA. The biotechnology firm reported preliminary 2025 revenue of approximately $113 million on February 23, representing a staggering 700% increase over the prior year. This growth is attributed to a sevenfold expansion in the drug's sales volume.

International Expansion and Quarterly Results

The revenue leap coincides with ANKTIVA's broadening global reach. Following recent approvals from both the European Commission and Saudi Arabia's drug authority, the treatment is now authorized for use in 33 countries.

Financially, the company reported $38.29 million in revenue for the fourth quarter alone. Its loss per share came in at $0.06, which was narrower than the anticipated $0.08 loss. ImmunityBio's stock closed at $11.55 on February 24, giving the company a market capitalization of $9.68 billion.

Analyst Upgrades and Insider Transactions

Market analysts swiftly revised their outlooks following the announcement. H.C. Wainwright established a price target of $15 per share, while D. Boral Capital set a more bullish target of $23. The current analyst consensus rating stands at "Moderate Buy," with an average price target of $12.60.

Alongside this positive business development, two board members executed share sales on February 23. Director Christobel Selecky sold 25,000 shares at $10 each, and Director Barry J. Simon divested 165,000 shares.